Q-omics provides the consensus-scored MIRLET7C profile across patient tissues and cancer cell-line models. MIRLET7C expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MIRLET7C is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, MIRLET7C RNA expression shows 13,638 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight COAD, KICH, and PDAC as cancer lineages where MIRLET7C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIRLET7C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIRLET7C survival associations across molecular data types. MIRLET7C RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIRLET7C RNA expression–survival associations across cancer types. High MIRLET7C expression shows unfavorable associations in COAD and BRCA, but favorable associations in KIRP, ACC, HNSC and ESCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for MIRLET7C RNA expression.
This table summarizes MIRLET7C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MIRLET7C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIRLET7C shows lower tumor expression in KICH, BRCA, UCEC, THCA and KIRP. The KICH box plot shows higher MIRLET7C RNA expression in normal versus tumor tissue (log2 FC = −0.555, t-test p < 0.001).
This table shows molecular features associated with MIRLET7C in patient tissues and cancer cell lines. In patient samples, MIRLET7C shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
